Liquamycin

Manufacturer
Zoetis Inc.
Effective date
2024-02-13
Label type
PRESCRIPTION ANIMAL DRUG LABEL
Version
11
Source
full-release
Hydrated at
2026-06-01 02:42:50

Label at a glance#

ProductLiquamycin LA-200
Active ingredientOXYTETRACYCLINE
Label structure15 sections

Dosage and administration

Liquamycin LA-200 is intended for use in the treatment of disease due to oxytetracycline-susceptible organisms in beef cattle; dairy cattle; calves, including preruminating (veal) calves; and swine. A thoroughly cleaned, sterile needle and syringe should be used for each injection (needles and syringes may be sterilized by boiling in water for 15 minutes). In cold weather, Liquamycin LA-200 should be warmed to roo...

Storage and handling

Store at room temperature 15°– 30°C (59°– 86°F). Protect from freezing. Use within 28 days of first vial puncture. Stopper may be punctured a maximum of 40 times.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Liquamycin® LA-200®
(oxytetracycline injection)
Antibiotic

Each mL contains 200 mg of oxytetracycline base as oxytetracycline dihydrate.

For the treatment of disease in beef cattle; dairy cattle; calves, including preruminating (veal) calves; and swine


CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

For animal use only

Read Entire Package Insert Carefully Before Using This Product

DESCRIPTION SECTION

Liquamycin LA-200 (oxytetracycline injection) is a sterile, ready-to-use solution for the administration of the broad-spectrum antibiotic oxytetracycline by injection.

Liquamycin LA-200 administered for the treatment of bacterial pneumonia (cattle or swine) or anaplasmosis (cattle) at a dosage of 9 mg of oxytetracycline per lb of body weight has been demonstrated in clinical trials to be as effective as 2 or 3 repeated, daily treatments at 3–5 mg/lb of body weight.

Liquamycin LA-200 does not require refrigeration; however, it is recommended that it be stored at room temperature, 15°– 30°C (59°– 86°F). The antibiotic activity of oxytetracycline is not appreciably diminished in the presence of body fluids, serum, or exudates.

CAUTION

SPL UNCLASSIFIED SECTION

When administered to cattle, muscle discoloration may necessitate trimming of the injection site(s) and surrounding tissues during the dressing procedure.

WARNINGS

WARNINGS SECTION

Discontinue treatment at least 28 days prior to slaughter of cattle and swine. Milk taken from animals during treatment and for 96 hours after the last treatment must not be used for food. Rapid intravenous administration may result in animal collapse. Oxytetracycline should be administered intravenously slowly over a period of at least 5 minutes.

PRECAUTIONS

PRECAUTIONS SECTION

Exceeding the highest recommended level of drug per lb of body weight per day, administering more than the recommended number of treatments, and/or exceeding 10 mL intramuscularly or subcutaneously per injection site in adult beef and dairy cattle, and 5 mL intramuscularly per injection site in adult swine, may result in antibiotic residues beyond the withdrawal period.

At the first sign of any adverse reaction, discontinue use of the product and seek the advice of your veterinarian. Some of the reactions may be attributed either to anaphylaxis (an allergic reaction) or to cardiovascular collapse of unknown cause.

Shortly after injection, treated animals may have transient hemoglobinuria resulting in darkened urine.

As with all antibiotic preparations, use of this drug may result in overgrowth of nonsusceptible organisms, including fungi. A lack of response by the treated animal, or the development of new signs, may suggest that an overgrowth of nonsusceptible organisms has occurred. If any of these conditions occur, consult your veterinarian.

Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving Liquamycin LA-200 in conjunction with penicillin. 

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Reports of adverse reactions associated with oxytetracycline administration include injection site swelling, restlessness, ataxia, trembling, swelling of eyelids, ears, muzzle, anus and vulva (or scrotum and sheath in males), respiratory abnormalities (labored breathing), frothing at the mouth, collapse and possibly death. Some of these reactions may be attributed to anaphylaxis (an allergic reaction) or to cardiovascular collapse of unknown cause.

STORAGE

STORAGE AND HANDLING SECTION

Store at room temperature 15°– 30°C (59°– 86°F).

Protect from freezing. Use within 28 days of first vial puncture. Stopper may be punctured a maximum of 40 times.

CARE OF SICK ANIMALS

SPL UNCLASSIFIED SECTION

The use of antibiotics in the management of diseases is based on an accurate diagnosis and an adequate course of treatment. When properly used in the treatment of diseases caused by oxytetracycline-susceptible organisms, most animals that have been treated with Liquamycin LA-200 show a noticeable improvement within 24–48 hours.

INDICATIONS

VETERINARY INDICATIONS SECTION

Liquamycin LA-200 is intended for use in the treatment of the following diseases in beef cattle; dairy cattle; calves, including preruminating (veal) calves; and swine when due to oxytetracycline-susceptible organisms: 

Cattle

SPL UNCLASSIFIED SECTION

Liquamycin LA-200 is indicated in the treatment of pneumonia and shipping fever complex associated with Pasteurella spp. and Hemophilus spp.; infectious bovine keratoconjunctivitis (pinkeye) caused by Moraxella bovis; foot rot and diphtheria caused by Fusobacterium necrophorum; bacterial enteritis (scours) caused by Escherichia coli; wooden tongue caused by Actinobacillus lignieresii; leptospirosis caused by Leptospira pomona; anaplasmosis caused by Anaplasma marginale; anthrax caused by Bacillus anthracis; and wound infections and acute metritis caused by strains of staphylococci and streptococci organisms sensitive to oxytetracycline.

Swine

SPL UNCLASSIFIED SECTION

Liquamycin LA-200 is indicated in the treatment of bacterial enteritis (scours, colibacillosis) caused by Escherichia coli; pneumonia caused by Pasteurella multocida; and leptospirosis caused by Leptospira pomona. 

In sows, Liquamycin LA-200 is indicated as an aid in the control of infectious enteritis (baby pig scours, colibacillosis) in suckling pigs caused by Escherichia coli.

DOSAGE

DOSAGE & ADMINISTRATION SECTION

Cattle

SPL UNCLASSIFIED SECTION

Liquamycin LA-200 is to be administered by intramuscular, subcutaneous, or intravenous injection. Intramuscular administration is not recommended according to Beef Quality Assurance Guidelines.

A single dose of 9 mg of oxytetracycline per lb of body weight administered intramuscularly or subcutaneously is recommended in the treatment of infectious bovine keratoconjunctivitis (pinkeye) caused by Moraxella bovis; and in the treatment of the following conditions where retreatment is impractical due to husbandry conditions, such as cattle on range, or where their repeated restraint is inadvisable: bacterial pneumonia caused by Pasteurella spp. (shipping fever) in calves and yearlings, and anaplasmosis caused by Anaplasma marginale.

Liquamycin LA-200 can also be administered by intravenous, subcutaneous, or intramuscular injection at a level of 3–5 mg of oxytetracycline per lb of body weight per day.

In the treatment of severe foot rot and advanced cases of other indicated diseases, a dosage level of 5 mg/lb of body weight per day is recommended. Treatment should be continued 24–48 hours following remission of disease signs; however, not to exceed a total of 4 consecutive days. Consult your veterinarian if improvement is not noted within 24–48 hours of the beginning of treatment.

Swine

SPL UNCLASSIFIED SECTION

A single dosage of 9 mg of Liquamycin LA-200 per lb of body weight administered intramuscularly in the neck region is recommended in the treatment of bacterial pneumonia caused by Pasteurella multocida in swine, where retreatment is impractical due to husbandry conditions or where repeated restraint is inadvisable.

Liquamycin LA-200 can also be administered by intramuscular injection at a level of 3–5 mg of oxytetracycline per lb of body weight per day. Treatment should be continued 24–48 hours following remission of disease signs; however, not to exceed a total of 4 consecutive days. Consult your veterinarian if improvement is not noted within 24–48 hours of the beginning of treatment.

For sows, administer once intramuscularly in the neck region 3 mg of oxytetracycline per lb of body weight approximately 8 hours before farrowing or immediately after completion of farrowing.

For swine weighing 25 lb of body weight and under, Liquamycin LA-200 should be administered undiluted for treatment at 9 mg/lb but should be administered diluted for treatment at 3 or 5 mg/lb.

9 mg/lb Dosage3 or 5 mg/lb Dosage
Volume of Undiluted Liquamycin LA-200Volume of Diluted Liquamycin LA-200
Body Weight9 mg/lb3 mg/lbDilution* 5 mg/lb
5 lb0.2 mL0.6 mL1:71.0 mL
10 lb0.5 mL0.9 mL1:51.5 mL
25 lb1.1 mL1.5 mL1:32.5 mL

* To prepare dilutions, add 1 part Liquamycin LA-200 to 3, 5, or 7 parts of sterile water, or 5% dextrose solution as indicated; the diluted product should be used immediately.

*To prepare dilutions, add 1 part Liquamycin LA-200 to 3, 5, or 7 parts of sterile water, or 5% dextrose solution as indicated; the diluted product should be used immediately.

DIRECTIONS FOR USE

DOSAGE & ADMINISTRATION SECTION

Liquamycin LA-200 is intended for use in the treatment of disease due to oxytetracycline-susceptible organisms in beef cattle; dairy cattle; calves, including preruminating (veal) calves; and swine. A thoroughly cleaned, sterile needle and syringe should be used for each injection (needles and syringes may be sterilized by boiling in water for 15 minutes). In cold weather, Liquamycin LA-200 should be warmed to room temperature before administration to animals. Before withdrawing the solution from the bottle, disinfect the rubber cap on the bottle with suitable disinfectant, such as 70% alcohol. The injection site should be similarly cleaned with the disinfectant. Needles of 16–18 gauge and 1–1½ inches long are adequate for intramuscular and subcutaneous injections. Needles 2–3 inches are recommended for intravenous use.

Intramuscular Administration

SPL UNCLASSIFIED SECTION

Intramuscular injections should be made by directing the needle of suitable gauge and length into the fleshy part of a thick muscle in the neck region; avoid blood vessels and major nerves. Before injecting the solution, pull back gently on the plunger. If blood appears in the syringe, a blood vessel has been entered; withdraw the needle and select a different site. In cattle, intramuscular administration is not recommended according to Beef Quality Assurance Guidelines. No more than 10 mL should be injected intramuscularly at any one site in adult beef and dairy cattle, and not more than 5 mL per site in adult swine; rotate injection sites for each succeeding treatment. The volume administered per injection site should be reduced according to age and body size so that 1-2 mL per site is injected in small calves.

Subcutaneous Administration

SPL UNCLASSIFIED SECTION

Subcutaneous injections in beef cattle, dairy cattle, and calves, including preruminating (veal) calves, should be made by directing the needle of suitable gauge and length through the loose folds of the neck skin in front of the shoulder. Care should be taken to ensure that the tip of the needle has penetrated the skin but is not lodged in muscle. Before injecting the solution, pull back gently on the plunger. If blood appears in the syringe, a blood vessel has been entered; withdraw the needle and select a different site. The solution should be injected slowly into the area between the skin and muscles. No more than 10 mL should be injected subcutaneously at any one site in adult beef and dairy cattle; rotate injection sites for each succeeding treatment. The volume administered per injection site should be reduced according to age and body size so that 1–2 mL per site is injected in small calves.

Intravenous Administration

SPL UNCLASSIFIED SECTION

Liquamycin LA-200 may be administered intravenously to beef and dairy cattle. As with all highly concentrated materials, Liquamycin LA-200 should be administered slowly by the intravenous route.

Preparation of the Animal for Injection

SPL UNCLASSIFIED SECTION

  1. Approximate location of vein. The jugular vein runs in the jugular groove on each side of the neck from the angle of the jaw to just above the brisket and slightly above and to the side of the windpipe (see Fig. I).
  2. Restraint. A stanchion or chute is ideal for restraining the animal. With a halter, rope, or cattle leader (nose tongs), pull the animal's head around the side of the stanchion, cattle chute, or post in such a manner to form a bow in the neck (see Fig. II), then snub the head securely to prevent movement. By forming the bow in the neck, the outside curvature of the bow tends to expose the jugular vein and make it easily accessible.
    Caution: Avoid restraining the animal with a tight rope or halter around the throat or upper neck which might impede blood flow. Animals that are down present no problem so far as restraint is concerned.
  3. Clip hair in area where injection is to be made (over the vein in the upper third of the neck). Clean and disinfect the skin with alcohol or other suitable antiseptic.
FIGURE IFIGURE IFIGURE IIFIGURE II
FIGURE IFIGURE II

Entering the Vein and Making the Injection

SPL UNCLASSIFIED SECTION

1. Raise the vein. This is accomplished by tying the choke rope tightly around the neck close to the shoulder. The rope should be tied in such a way that it will not come loose and so that it can be untied quickly by pulling the loose end (see Fig. II). In thick-necked animals, a block of wood placed in the jugular groove between the rope and the hide will help considerably in applying the desired pressure at the right point. The vein is a soft flexible tube through which blood flows back to the heart. Under ordinary conditions it cannot be seen or felt with the fingers. When the flow of blood is blocked at the base of the neck by the choke rope, the vein becomes enlarged and rigid because of the back pressure. If the choke rope is sufficiently tight, the vein stands out and can be easily seen and felt in thin-necked animals. As a further check in identifying the vein, tap it with the fingers in front of the choke rope. Pulsations that can be seen or felt with the fingers in front of the point being tapped will confirm the fact that the vein is properly distended. It is impossible to put the needle into the vein unless it is distended. Experienced operators are able to raise the vein simply by hand pressure, but the use of a choke rope is more certain.

2. Inserting the needle. This involves 3 distinct steps. First, insert the needle through the hide. Second, insert the needle into the vein. This may require 2 or 3 attempts before the vein is entered. The vein has a tendency to roll away from the point of the needle, especially if the needle is not sharp. The vein can be steadied with the thumb and finger of one hand. With the other hand, the needle point is placed directly over the vein, slanting it so that its direction is along the length of the vein, either toward the head or toward the heart. Properly positioned this way, a quick thrust of the needle will be followed by a spurt of blood through the needle, which indicates that the vein has been entered. Third, once in the vein, the needle should be inserted along the length of the vein all the way to the hub, exercising caution to see that the needle does not penetrate the opposite side of the vein. Continuous steady flow of blood through the needle indicates that the needle is still in the vein. If blood does not flow continuously, the needle is out of the vein (or clogged) and another attempt must be made. If difficulty is encountered, it may be advisable to use the vein on the other side of the neck.

3. While the needle is being placed in proper position in the vein, an assistant should get the medication ready so that the injection can be started without delay after the vein has been entered.

4. Making the injection. With the needle in position as indicated by continuous flow of blood, release the choke rope by a quick pull on the free end. This is essential—the medication cannot flow into the vein while it is blocked. Immediately connect the syringe containing Liquamycin LA-200 to the needle and slowly depress the plunger. If there is resistance to depression of the plunger, this indicates that the needle has slipped out of the vein (or is clogged) and the procedure will have to be repeated. Watch for any swelling under the skin near the needle, which would indicate that the medication is not going into the vein. Should this occur, it is best to try the vein on the opposite side of the neck.

5. Removing the needle. When injection is complete, remove needle with straight pull. Then apply pressure over area of injection momentarily to control any bleeding through needle puncture, using cotton soaked in alcohol or other suitable antiseptic.

SPL UNCLASSIFIED SECTION

Not For Human Use

Approved by FDA under NADA # 113-232

 Distributed by:
Zoetis Inc.
Kalamazoo, MI 49007

Take Time
Take Time

Revised: October 2022

40039386

PRINCIPAL DISPLAY PANEL - 100 mL Carton Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

40039384

100 mL Carton Label
100 mL Carton Label

PRINCIPAL DISPLAY PANEL - 250 mL Carton Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

40039387

250 mL Carton Label
250 mL Carton Label

PRINCIPAL DISPLAY PANEL - 500 mL Carton Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

40039389

500 mL Carton Label
500 mL Carton Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
248390oxytetracycline 200 MG in 1 mL Injectable SolutionPSN11
631403oxytetracycline 200 MG/ML Injectable Solution [Liquamycin]SBD11
248390oxytetracycline 200 MG/ML Injectable SolutionSCD11
631403Liquamycin 200 MG/ML Injectable SolutionSY11
248390oxytetracycline 200 MG per 1 ML Injectable SolutionSY11

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
e2db08c6-133f-4f4f-afb4-e90a2418d6f6Product name120230320
11ed6f83-cdd2-4637-8379-b1a1d3ae3cdeProduct name120181101
86c45a79-b9f0-4476-a27c-6e10db098497Product name120180125

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
54771-1140-1LiquamycinLA-200100 mL in 1 VIAL, GLASSINJECTION, SOLUTION10011
54771-1140-2LiquamycinLA-200250 mL in 1 VIAL, GLASSINJECTION, SOLUTION25011
54771-1140-3LiquamycinLA-200500 mL in 1 VIAL, GLASSINJECTION, SOLUTION50011

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
54771-1140LIQUAMYCIN LA-200 (OXYTETRACYCLINE) INJECTION, SOLUTION [ZOETIS INC.]113 package rows20240214_d14180ed-329c-464a-a9ac-b7bbf3d59536.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
oxytetracyclineACTIVE INGREDIENTX20I9EN9551
oxytetracycline anhydrousACTIVE MOIETYSLF0D9077S1
hydrochloric acidINACTIVE INGREDIENTQTT17582CB1
magnesium oxideINACTIVE INGREDIENT3A3U0GI71G1
monoethanolamineINACTIVE INGREDIENT5KV86114PT1
povidonesINACTIVE INGREDIENTFZ989GH94E1
pyrrolidoneINACTIVE INGREDIENTKKL5D39EOL1
sodium formaldehyde sulfoxylateINACTIVE INGREDIENTX4ZGP7K7141

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
54771-114054771-1140-1, 54771-1140-2, 54771-1140-3

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 4 · 193 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / RETROBULBARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSOLUTION / INTRAPERITONEALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSOLUTION / URETERALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
povidonesPOVIDONEFZ989GH94EFILM, EXTENDED RELEASE / TRANSDERMALNAExact identifier — unii candidate
30 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBAEROSOL, SPRAY / RESPIRATORY (INHALATION)1.5 %w/wExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS5 mgExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRAVENOUS720 mgExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / INTRADERMALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
povidonesPOVIDONEFZ989GH94ECAPSULE / ORAL300 mgExact identifier — unii candidate
30 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRABURSALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
povidonesPOVIDONEFZ989GH94ETROCHE / ORAL30 mgExact identifier — unii candidate
30 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBOINTMENT / TOPICALNAExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / SUBMUCOSALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
magnesium oxideMAGNESIUM OXIDE3A3U0GI71GTABLET, FILM COATED / ORAL80 mgExact identifier — unii candidate
9 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / INTRACAUDALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRACARDIACADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRA-ARTERIAL840 mgExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRACAUDALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS160 mgExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBPOWDER / INTRAVENOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSUSPENSION/ DROPS / OPHTHALMICADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
sodium formaldehyde sulfoxylateSODIUM FORMALDEHYDE SULFOXYLATEX4ZGP7K714INJECTION / INTRAVENOUS3 mgExact identifier — unii candidate
5 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / INFILTRATION0.37 %w/vExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBCAPSULE / ORAL7 mgExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / PARENTERALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSOLUTION / INTRAOCULARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / INTRAVENOUS0.18 %w/vExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBLIQUID / INTRAMUSCULARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / EPIDURALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, SOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBGEL / OPHTHALMICADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR5 mgExact identifier — unii candidate
148 equally ranked IID candidates
povidonesPOVIDONEFZ989GH94ECAPSULE, COATED, EXTENDED RELEASE / ORALNAExact identifier — unii candidate
30 equally ranked IID candidates
sodium formaldehyde sulfoxylateSODIUM FORMALDEHYDE SULFOXYLATEX4ZGP7K714INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS11 mgExact identifier — unii candidate
5 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSPRAY, METERED / RESPIRATORY (INHALATION)ADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
povidonesPOVIDONEFZ989GH94EIMPLANT / SUBCUTANEOUS6 mgExact identifier — unii candidate
30 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRASPINALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, EMULSION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION, POWDER, FOR SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
povidonesPOVIDONEFZ989GH94ETABLET, DELAYED RELEASE / ORAL53 mgExact identifier — unii candidate
30 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBLIQUID / NASALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSOLUTION / INTRAVASCULARADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSPRAY, METERED / NASALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / SUBMUCOSALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
magnesium oxideMAGNESIUM OXIDE3A3U0GI71GCAPSULE, EXTENDED RELEASE / ORAL75 mgExact identifier — unii candidate
9 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBEMULSION / OPHTHALMICADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSUSPENSION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / SUBCONJUNCTIVALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
povidonesPOVIDONEFZ989GH94ESUSPENSION / AURICULAR (OTIC)NAExact identifier — unii candidate
30 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / INTRAMUSCULAR306 mgExact identifier — unii candidate
148 equally ranked IID candidates
povidonesPOVIDONEFZ989GH94ETABLET, ORALLY DISINTEGRATING / ORAL15.03 mgExact identifier — unii candidate
30 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSOLUTION / RECTALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
povidonesPOVIDONEFZ989GH94ECAPSULE, DELAYED RELEASE PELLETS / ORAL32 mgExact identifier — unii candidate
30 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBPOWDER, FOR SUSPENSION / ENDOTRACHEALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBSPRAY / RESPIRATORY (INHALATION)ADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTION / URETHRALADJ PHExact identifier — unii candidate
148 equally ranked IID candidates
magnesium oxideMAGNESIUM OXIDE3A3U0GI71GTABLET, DELAYED RELEASE / ORAL368 mgExact identifier — unii candidate
9 equally ranked IID candidates
hydrochloric acidHYDROCHLORIC ACIDQTT17582CBINJECTABLE, LIPOSOMAL / INTRAVENOUSADJ PHExact identifier — unii candidate
148 equally ranked IID candidates

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.